首页> 中文期刊> 《新医学》 >比索洛尔对病情稳定的 COPD 致肺源性心脏病患者心率变异性的影响

比索洛尔对病情稳定的 COPD 致肺源性心脏病患者心率变异性的影响

         

摘要

Objective To investigate the effect of high cardiovascular-selective β-blocker bisoprolol on heart rate variability (HRV) in patients with stable pulmonary heart disease (PHD) induced by chronic obstructive pulmonary disease ( COPD).Methods A total of 36 patients with stable PHD induced by COPD were recruited in this study from 2011.1 to 2012.7.All patients were administrated with bisoprolol (2.5mg, once daily) on the basis of standard treatment to PHD , COPD and the concomitant diseases.All subjects were followed up for 4 weeks.The HRV and forced expiratory volume in the first second (FEV1) were examined in all subjects at enrollment and at the end of study.Results In comparison with the levels at enrollment , the levels of HRV at the end of study were significantly improved , P<0.05.There were no significant differences on FEV1 between the levels at the beginning and end of study , P>0.05.Conclusion The levels of HRV might be improve by Bisoprolol in patients with stable PHD induced by COPD.%目的:探讨高心血管选择性β受体阻断药比索洛尔对病情稳定的COPD致肺源性心脏病患者心率变异性( HRV)的影响。方法选择2011年1月至2012年7月治疗稳定的COPD致肺源性心脏病患者36例。患者在规范的COPD、肺源性心脏病及其合并症治疗基础上,加用比索乐尔2.5 mg,随访4周,研究前后所有患者均行动态心电图及FEV1检查。结果与研究前比较,研究结束时,患者HRV明显改善,差异有统计学意义( P<0.05);患者治疗前后FEV1比较,差异无统计学意义( P>0.05)。结论比索洛尔能改善病情稳定的COPD致肺源性心脏病患者HRV。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号